Critical Pharmaceuticals is a spin-out company from the University of Nottingham. It is a biotechnology company with proprietary drug delivery technologies for injectable sustained release and nasal delivery of challenging drugs including proteins and peptides. They are developing a number of ground breaking products to treat various diverse diseases.
Critical Pharmaceuticals have agreed licensing terms with a US-based investment group to develop an anti-obesity nasal spray based on the company's CriticalSorbTM delivery technology.
Critical Pharmaceuticals' novel nasal drug delivery system CriticalSorbTM was discovered last year. It allows protein drugs to be absorbed directly into the bloodstream via the nasal cavity and has opened up the possibility of develeoping nasal sprays as an alternative to daily injection for drugs such as insulin and human growth hormone.
Lisbeth Illum, the CEO of Critical Pharmaceuticals, explained: "an increasing proportion of drugs in development are biopharmaceuticals and improved delivery methods are needed that avoid the patients having to inject themselves daily. The CriticalSorbTM nasal delivery system for biopharmaceuticals is an example of a non-invasive system that is easy for the patient to administer.. Our license with major US companies, for both our CriticalSorbTM and CriticalMixTM technologies, shows the need for such novel and inventive delivery systems."
Follow this link to find out more about Critical Pharmaceuticals
Posted on Tuesday 8th September 2009